Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $9.75 USD
Change Today +0.28 / 2.96%
Volume 23.3K
ICAD On Other Exchanges
Symbol
Exchange
NASDAQ CM
Stuttgart
As of 8:10 PM 04/20/15 All times are local (Market data is delayed by at least 15 minutes).

icad inc (ICAD) Key Developments

iCAD, Inc. Reports Unaudited Consolidated Financial Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Earnings Guidance for Fiscal Year 2015

iCAD, Inc. reported unaudited consolidated financial results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported total revenue of $13,165,000 against $9,135,000 a year ago. Income from operations was $515,000 against loss from operations of $621,000 a year ago. Loss before income tax expense was $37,000 against $4,360,000 a year ago. Net loss was $96,000 or $0.01 per basic and diluted share against $4,410,000 or $0.41 per basic and diluted share a year ago. Non GAAP adjusted EBITDA was $2,464,000 against $285,000 a year ago. Non GAAP adjusted net income was $107,000 against non GAAP adjusted net loss of $1,478,000 a year ago. Non GAAP adjusted net income per share was $0.01 against loss per share of $0.14 per share a year ago. The company generated $3.4 million of cash from operations. For the year, the company reported total revenue of $43,924,000 against $33,067,000 a year ago. Income from operations was $815,000 against loss from operations of $1,776,000 a year ago. Loss before income tax expense was $856,000 against $7,482,000 a year ago. Net loss was $1,009,000 or $0.07 per basic and diluted share against $7,608,000 or $0.70 per basic and diluted share a year ago. Net cash provided by operating activities was $3,204,000 against cash used for operating activities of $1,433,000 a year ago. Additions to property and equipment were $1,214,000 against $539,000 a year ago. Non GAAP adjusted EBITDA was $6,382,000 against $1,856,000 a year ago. Non GAAP adjusted net loss was $1,218,000 against $5,160,000 a year ago. Non GAAP adjusted net income per share was $0.09 against $0.48 per share a year ago. Revenue growth continues to be driven by strong trends in recurring services revenue, with recurring services revenue growing 104% in the quarter and 74% for the year. The company expects revenue for fiscal year 2015 to be in the range of $55 million to $59 million, representing growth of 25% to 34% compared to 2014. The company expects adjusted EBITDA margin in the 16% to 20% range.

iCAD, Inc. to Report Q4, 2014 Results on Feb 24, 2015

iCAD, Inc. announced that they will report Q4, 2014 results After-Market on Feb 24, 2015

iCAD, Inc., Q4 2014 Earnings Call, Feb 24, 2015

iCAD, Inc., Q4 2014 Earnings Call, Feb 24, 2015

iCAD, Inc. Presents at 27th Annual ROTH Conference, Mar-11-2015 09:30 AM

iCAD, Inc. Presents at 27th Annual ROTH Conference, Mar-11-2015 09:30 AM. Venue: The Ritz Carlton, 1 Ritz Carlton Dr, Dana Point, CA 92629, United States. Speakers: Kenneth M. Ferry, Chief Executive Officer, President and Director.

iCAD, Inc. Announces More than 500 Patients Treated in Study of Intraoperative Radiation Therapy for Early-Stage Breast Cancer

iCAD, Inc. announced that more than 500 patients have been treated in its clinical trial of intraoperative radiation therapy (IORT) using the Xoft® Axxent® Electronic Brachytherapy (eBx®) System®. The study, 'A Safety and Efficacy Study of Intra-Operative Radiation Therapy (IORT) Using the Xoft Axxent eBx System at the Time of Breast Conservation Surgery for Early-Stage Breast Cancer (the ExBRT study),' compares the Xoft System to traditional external beam radiation therapy (EBRT). Patients in the study were treated with a targeted, single-fraction dose of radiation using the Xoft System at the time of lumpectomy. With the Xoft System, patients are treated with one dose directly to the tumor bed at the time of lumpectomy, thereby reducing the risk to nearby healthy tissue and organs such as the heart, lung, and ribs. Using the Xoft System also improves patient quality of life by reducing the number of treatments compared to EBRT, which usually requires 30-35 daily treatments over a period of 5-7 weeks. To date, more than 10,000 patients have been treated globally, across all clinical applications, with the Xoft System. Researchers plan to enroll up to 1,000 patients across the U.S. and Europe. Currently, the study includes 23 active centers. Study subjects will be followed for 10 years after treatment to evaluate the long-term safety and efficacy of breast IORT with the Xoft System. The study will also assess cosmetic outcomes and quality of life for those treated with Xoft IORT.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ICAD:US $9.75 USD +0.28

ICAD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Hologic Inc $33.08 USD +0.62
View Industry Companies
 

Industry Analysis

ICAD

Industry Average

Valuation ICAD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.4x
Price/Book 2.3x
Price/Cash Flow 58.8x
TEV/Sales 2.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ICAD INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.